Deans' stroke musings: Icometrix announces ischaemic stroke solution

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, February 25, 2021

Icometrix announces ischaemic stroke solution

I wondered if it does white matter damage from the stroke. It does find white matter hyperintensities from this research.

How does icobrain enhance your radiological reporting for MS?

Because if white matter damage is found then that requires different protocols to solve. And your doctor has none.

The latest here:

Icometrix announces ischaemic stroke solution

In a press release, icometrix announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. According to the company, this announcement follows clearance from the US Food and Drug Administration (FDA) and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computer tomography (CT) perfusion scans in patients with ischaemic stroke.

According to icometrix, the icobrain cva is a fully-automated software solution for the quantitative assessment of tissue perfusion on CT. The company claims that icobrain cva reports the volume of the core and perfusion lesion by quantifying reduced cerebral blood flow, volume, and transit time. Additionally, icometrix states the report includes information on the correctness of the selected arterial input function and the quality of the output.

The press release details that icobrain cva provides physicians with fast, fully automated, and state-of-the-art insights to support treatment decisions in acute ischaemic stroke. It is further stated that the automated assessment of tissue parameters in an acute clinical setting by icobrain cva will allow more patients to get the right treatment and can improve patient outcomes and care while increasing efficiency.

“With the launch of icobrain cva we address a persisting need in the treatment of acute ischaemic stroke. By democratising advanced CT perfusion analysis for healthcare systems worldwide, we take the next step in our mission to become a holistic brain solution provider,” says Wim Van Hecke, CEO at icometrix, Antwerp, Belgium.

“The main challenge of current stroke solutions is correctly identifying the entry point of the injected contrast in the brain. icobrain cva introduces new, patented, deep learning technology into this identification process to achieve a more robust assessment of the infarcted area,” states Dirk Smeets, CTO at icometrix, Leuven, Belgium.